Pemetrexed

證據等級: L5

預測適應症: 10 個

Pemetrexed: From Pleural Mesothelioma to Malignant Peritoneal Mesothelioma

One-Sentence Summary

Pemetrexed (DB00642) is a multitargeted antifolate chemotherapy agent originally approved (as Alimta®) for pleural mesothelioma and non-small cell lung cancer. The TxGNN model predicts it may also be effective for Malignant Peritoneal Mesothelioma, with 11 clinical trials and 20 publications currently supporting this direction.

Quick Overview

Item	Content
Original Indication	Pleural Mesothelioma (with cisplatin) / Non-Small Cell Lung Cancer (per evidence-pack mechanistic rationale; not separately confirmed by regulatory license data)
Predicted New Indication	Malignant Peritoneal Mesothelioma
TxGNN Prediction Score	99.99%
Evidence Level	L2
US Market Status	Not Marketed (per current dataset — flagged for verification, see Next Steps)
Number of NDAs	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism of action (MOA) data for pemetrexed is not available from DrugBank in this evidence pack (data gap, severity: High). Based on the evidence pack’s repurposing rationale, pemetrexed is known as a multitargeted antifolate that inhibits thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT) — enzymes essential for folate-dependent DNA synthesis in rapidly dividing cells. This mechanism underlies its established, FDA-approved use in pleural mesothelioma (in combination with cisplatin).

Peritoneal mesothelioma and pleural mesothelioma belong to the same mesothelioma disease family, sharing identical histology and molecular biology and differing only in anatomical location (pleura vs. peritoneum). Because pemetrexed’s antifolate mechanism suppresses tumor cell proliferation in a manner independent of anatomical site, its efficacy is expected to translate across both sites. Clinically, this extrapolation is already widespread: cisplatin-pemetrexed is commonly used off-label for peritoneal mesothelioma, and the NCCN guideline lists it as a treatment option. This makes the TxGNN prediction mechanistically well-supported and clinically plausible rather than speculative.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00061477	Phase 2	Completed	48	First-line pemetrexed + gemcitabine, explicitly enrolling malignant pleural and peritoneal mesothelioma patients
NCT05001880	Phase 2	Recruiting	66	Randomized trial of neoadjuvant/palliative carboplatin+pemetrexed+bevacizumab ± atezolizumab specifically in peritoneal mesothelioma
NCT06057935	Phase 2	Recruiting	64	Randomized comparison of intraperitoneal vs. IV chemotherapy (pemetrexed-containing) after CRS+HIPEC for peritoneal mesothelioma
NCT00402766	Phase 1	Completed	19	Cisplatin + pemetrexed + imatinib safety/MTD study in unresectable or metastatic mesothelioma
NCT02029690	Phase 1	Terminated	85	ADI-PEG20 + pemetrexed + cisplatin in arginine-requiring tumors, including a peritoneal mesothelioma dose-escalation cohort
NCT02535312	Phase 1/2	Active, not recruiting	30	Methoxyamine (TRC102) + pemetrexed/cisplatin in solid tumors and mesothelioma refractory to standard chemotherapy
NCT03564691	Phase 1	Completed	470	Broad basket study of MK-4830 ± pembrolizumab in advanced solid tumors (mesothelioma-adjacent)
NCT04462809	Phase 2	Unknown	40	Three-cohort maintenance talazoparib following first-line platinum chemo in pleural/peritoneal mesothelioma
NCT06543069	Phase 2	Recruiting	28	Sintilimab + bevacizumab + pemetrexed + cisplatin in unresectable peritoneal mesothelioma, biomarker exploration
NCT03875144	Phase 2	Suspended	66	MESOTIP trial: PIPAC + systemic chemo (cisplatin+pemetrexed) vs. systemic chemo alone as 1st-line for peritoneal mesothelioma

Literature Evidence

PMID	Year	Type	Journal	Key Findings
28594258	2017	Retrospective study	Expert Rev Anticancer Ther	Retrospective evaluation of first-line pemetrexed + cisplatin efficacy specifically in MPeM
31287877	2019	Retrospective study	Jpn J Clin Oncol	Efficacy and safety of pemetrexed + cisplatin as first-line chemotherapy in advanced MPeM
41133016	2025	Comparative study	Clin Med Insights Oncol	Head-to-head comparison of pemetrexed-platinum vs. gemcitabine-platinum as first-line regimens in MPeM
33743636	2021	Retrospective study	BMC Cancer	Second-line treatment efficacy and prognostic factors following first-line cisplatin+pemetrexed in MPeM
38806763	2024	Multi-center study	Ann Surg Oncol	Demographic, clinicopathologic, and treatment outcome analysis across MPeM patients
26941986	2016	Review	J Gastrointest Oncol	Diagnosis and management overview of MPeM including chemotherapy role
35407498	2022	Review	J Clin Med	Treatment review of MPeM patients including systemic chemotherapy options
30450291	2018	Review	Transl Lung Cancer Res	General review of MPeM epidemiology, pathology, and treatment
34723916	2022	Case series	J Immunother	Chemoimmunotherapy in platinum-nonresponsive metastatic MPeM after prior pemetrexed-based regimens
23291819	2013	Case report	BMJ Case Rep	MPeM patient responding to rechallenge with cisplatin + pemetrexed, with literature review

Cytotoxicity

Item	Content
Cytotoxicity Classification	Conventional cytotoxic (multitargeted antifolate)
Myelosuppression Risk	High — neutropenia, thrombocytopenia, and anemia are well-documented with pemetrexed, particularly without vitamin B12/folic acid prophylaxis
Emetogenicity Classification	Low to moderate
Monitoring Items	CBC with differential, renal function (creatinine clearance), vitamin B12/folate status, liver function
Handling Protection	Must follow standard cytotoxic drug handling regulations (hazardous drug precautions)

Note: Specific toxicity data was not available in the evidence pack (DrugBank MOA/toxicity data gap); the above reflects the established pharmacological class of pemetrexed. Please cross-check against the package insert.

Safety Considerations

Please refer to the package insert for safety information. Key warnings, contraindications, and drug-drug interaction data were not available in the current evidence pack (data gap DG001, severity: Blocking).

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The top-ranked prediction (Malignant Peritoneal Mesothelioma) has L2-level evidence, including a Phase 2 completed trial with peritoneal mesothelioma patients explicitly enrolled (NCT00061477) and multiple ongoing Phase 2 trials designed specifically for this indication. The mechanistic rationale — extrapolation from the FDA-approved pleural mesothelioma indication to the same disease family at a different anatomical site — is strong and already reflected in NCCN guideline listing and off-label clinical practice.

To proceed, the following is needed:

Confirmed mechanism of action (MOA) data from DrugBank (currently blocking gap DG002)
TFDA/FDA package insert data: key warnings, contraindications, and drug-drug interactions (currently blocking gap DG001)
Verification of “Not Marketed” market status against known FDA approval history for pemetrexed (Alimta®) — this appears inconsistent with the drug’s well-established regulatory record and should be re-checked at the data source
Route compatibility data for the intraperitoneal chemotherapy protocols referenced in several trials (e.g., NCT06057935, NCT03875144)
Subtype-specific evidence review, since other predicted indications in this pack (e.g., pleural sarcomatoid mesothelioma, pleural biphasic mesothelioma) show materially weaker chemotherapy response and warrant separate risk-benefit assessment
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.